Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05416775 | Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 168 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 19, 2022 | clinicaltrials |
| NCT05507606 | Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations | unknown | Phase 2 | 50 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 19, 2022 |
| clinicaltrials |
| NCT04122833 | Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study | unknown | — | 80 | Konkuk University Medical CenterOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05380024 | A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer | unknown | Phase 2 | 10 | Peking University Cancer Hospital & InstituteOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT04749394 | A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy | unknown | Phase 2 | 42 | Chinese Academy of Medical SciencesOTHER | 1 | Aug 16, 2022 | clinicaltrials |
| NCT05332574 | A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor | unknown | Phase 1 / Phase 2 | 120 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Aug 5, 2022 | clinicaltrials |
| NCT05117658 | Study of HA121-28 in Patients With Non-Small Cell Lung Cancer | unknown | Phase 2 | 83 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Aug 4, 2022 | clinicaltrials |
| NCT05255406 | Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE) | unknown | Phase 2 | 62 | Fudan UniversityOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT05486988 | ctDNA as a Biomarker for Treatment in Advanced NSCLC | unknown | — | 500 | Fuzhou General HospitalOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT05485350 | Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 32 | Peking University Third HospitalOTHER | 0 | Aug 3, 2022 | clinicaltrials |
| NCT05430009 | Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer | unknown | Phase 1 | 12 | VA Ann Arbor Healthcare SystemFED | 1 | Aug 1, 2022 | clinicaltrials |
| NCT05482087 | A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC | unknown | Phase 2 | 190 | Xuanzhu Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 1, 2022 | clinicaltrials |
| NCT04197076 | Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer Stages IIB-IIIB | unknown | — | 200 | Shanghai Chest HospitalOTHER | 1 | Jul 29, 2022 | clinicaltrials |
| NCT05477615 | Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases | unknown | Phase 2 | 28 | Jin Hyoung KangOTHER | 1 | Jul 28, 2022 | clinicaltrials |
| NCT03971175 | Influence of Biopsy Technique on Moleculargenetic Tumor Characterisation in NSCLC(PROFILER) | unknown | N/A | 540 | University Hospital TuebingenOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT05068024 | A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer(FWD1509) | unknown | Phase 1 / Phase 2 | 30 | Forward Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 26, 2022 | clinicaltrials |
| NCT05458726 | Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLC | unknown | Phase 2 | 80 | Peking Union Medical CollegeOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT05472467 | Camrelizumab Combination With SBRT and Concurrent Chemotherapy Treated Stage IV Oligometastatic Non-small Cell Lung Cancer(IMCORT-2) | unknown | Phase 2 | 35 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT05468294 | F16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung Cancer(Nivokin) | unknown | Phase 1 / Phase 2 | 3 | Philogen S.p.A.INDUSTRY | 1 | Jul 21, 2022 | clinicaltrials |
| NCT05460481 | Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors | unknown | Phase 2 | 29 | Hunan Cancer HospitalOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT05460195 | Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation | unknown | Phase 2 | 42 | Shanghai Chest HospitalOTHER | 1 | Jul 15, 2022 | clinicaltrials |
| NCT05273814 | Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung Cancer | unknown | Phase 1 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 13, 2022 | clinicaltrials |
| NCT04459611 | Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC（neoSCORE）(neoSCORE) | unknown | Phase 2 | 60 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 12, 2022 | clinicaltrials |
| NCT05451056 | An Open-label, Phase 2trial of Sotorasib in KRAS G12C-mutant Non-small-cell Lung Cancer(NSCLC) Patients and a Translational Study to Find Acquired Resistance Mechanism to Sotorasib(breakthrough) | unknown | Phase 2 | 37 | Yonsei UniversityOTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT05448781 | Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced NSCLC | unknown | Phase 2 | 38 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | Jul 7, 2022 | clinicaltrials |
| NCT05400304 | Radiomics Combined With Frozen Section Prediction Model for Spread Through Air Space in Lung Adenocarcinoma | unknown | — | 900 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Jun 29, 2022 | clinicaltrials |
| NCT05435274 | Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 380 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 28, 2022 | clinicaltrials |
| NCT05426317 | Exploratory Interventional Study of Prognostic Serum Biomarkers of Cancer Progression(Onco-PDL1s/B2M) | unknown | N/A | 100 | University Hospital, Clermont-FerrandOTHER | 1 | Jun 22, 2022 | clinicaltrials |
| NCT05369312 | Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients | unknown | Phase 1 | 230 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 21, 2022 | clinicaltrials |
| NCT05414630 | A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer | unknown | Phase 2 | 30 | Anhui Provincial Cancer HospitalOTHER | 1 | Jun 10, 2022 | clinicaltrials |
| NCT05411276 | A Real-World Study of Pyrotinib Maleate in the Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer With Rare Mutations in HER2 | unknown | — | 15 | Beijing Chest HospitalOTHER | 0 | Jun 9, 2022 | clinicaltrials |
| NCT05394233 | Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC | unknown | Phase 2 | 20 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | May 27, 2022 | clinicaltrials |
| NCT05395611 | Exhaled Breath Particles in Lung Cancer | unknown | — | 300 | Lund University HospitalOTHER | 1 | May 27, 2022 | clinicaltrials |
| NCT05387044 | SBRT for Oligoprogressive NSCLC After First Line Treatment With Immune Checkpoint Inhibitors | unknown | Phase 2 | 28 | Zhejiang Cancer HospitalOTHER | 1 | May 24, 2022 | clinicaltrials |
| NCT05387109 | Penpulimab Combined With Anlotinib in Neoadjuvant Treatment of Resectable Non-small Cell Lung Cancer(pcwaintrl) | unknown | Phase 4 | 41 | Tang-Du HospitalOTHER | 0 | May 24, 2022 | clinicaltrials |
| NCT05085054 | Salvage Surgery Following Downstaging of Advanced Non-small Cell Lung Cancer by Targeted Therapy (SDANT) | unknown | Phase 2 | 30 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | May 20, 2022 | clinicaltrials |
| NCT05319886 | Observational Study of the Efficacy and Safety of Anlotinib Combined With Penpulimab in Elderly Lung Cancer Patients(AP) | unknown | — | 40 | The First Affiliated Hospital of Xinxiang Medical CollegeOTHER | 1 | May 20, 2022 | clinicaltrials |
| NCT05377788 | Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung Cancer | unknown | — | 900 | Samsung Medical CenterOTHER | 1 | May 19, 2022 | clinicaltrials |
| NCT05380271 | Efficacy and Safety of DEB-BACE With Sequential Arotinib and Tirelizumab in the Treatment of Advanced NSCLC | unknown | Phase 2 | 60 | Gang WuOTHER | 0 | May 18, 2022 | clinicaltrials |
| NCT04052412 | Biodistribution and Kinetics of 18F-AraG in Non-Small Cell Lung Cancer | unknown | Phase 1 | 2 | University of TennesseeOTHER | 1 | May 13, 2022 | clinicaltrials |
| NCT03606239 | NSCLC Isotoxic Hypofractionated Chemoradiotherapy(IHRC) | unknown | N/A | 30 | The Second Hospital of Hebei Medical UniversityOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT03606291 | NSCLC Isotoxic Hypofractionated Radiotherapy(IHR) | unknown | N/A | 30 | The Second Hospital of Hebei Medical UniversityOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT05360979 | A Clinical Study of Immunotherapy Combined With Chemotherapy and Anti-angiogenic Therapy in Operable NSCLC | unknown | Phase 2 | 42 | Second Xiangya Hospital of Central South UniversityOTHER | 1 | May 4, 2022 | clinicaltrials |
| NCT02562963 | Clinical Efficacy and Safety of NKT Cell Infusion in Patients With Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 120 | Minghui ZhangOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT04878107 | SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy(SABRE) | unknown | Phase 2 | 88 | Wuhan UniversityOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT03563482 | Correlation of Metabolic Imaging With Immune Markers in NSCLC Candidate to Immunotherapy. | unknown | N/A | 500 | Istituto Clinico HumanitasOTHER | 1 | Apr 28, 2022 | clinicaltrials |
| NCT05351320 | WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC | unknown | Phase 2 | 40 | Jinming YuOTHER | 1 | Apr 28, 2022 | clinicaltrials |
| NCT03997799 | Comparison of Two Techniques of Uniportal VATS Lobectomies for Clinical Stage I Non-Small Cell Lung Cancer | unknown | N/A | 20 | Pulmonary Hospital ZakopaneOTHER | 1 | Apr 26, 2022 | clinicaltrials |
| NCT04743752 | Obstructive Sleep Apnea Influences Efficacy of PD-1-Based Immunotherapy Against Non-Small Cell Lung Cancer | unknown | — | 200 | Peking University First HospitalOTHER | 1 | Apr 26, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Aug 19, 2022source: clinicaltrials